San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
The response rate in the control cohort is in line with historical data on azacitidine. Investors, already burnt by setbacks ...
Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology Association Congress and received FDA guidance for a future ...
15h
Edward White, an analyst from H.C. Wainwright, reiterated the Buy rating on Syndax Pharmaceuticals (SNDX – Research Report). The ...
The study is testing the drug in certain patients with relapsed or refractory acute myeloid leukemia (AML). The small ...
Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...
A patient with acute myeloid leukemia received a bone marrow transplant from a deceased donor, achieved engraftment, and has ...
On Tuesday, Syndax Pharmaceuticals Inc (NASDAQ:SNDX) revealed topline results from the relapsed or refractory (R/R) mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback